Myopia Progression
33
9
16
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 33 trials
100.0%
+13.4% vs benchmark
12%
4 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (33)
Comparing Myopia Control Spectacle Lenses and Standard Single Vision Spectacle Lenses in Children With Myopia
The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children
Contact Lenses to Slow Myopia Progression in Adults
The A.R.R.E.S.T.® Contact Lens Study
Management of Myopia in University Students With DIMS-TED Spectacle Lenses
Inhibition of Myopia Progression With Optical Devices
Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression
The A.R.R.E.S.T.® Spectacle Film Study
The P.A.U.S.E.® Spectacle Study
Spectacle Lens Visual Acuity Assessments Study
Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness
Myopia Control Spectacle Lens Cessation Study
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
Children's Viewing Behavior
Evaluation of the Effectiveness of a New Generation of Myopia Control Lens on the Progression of Myopia in Children Aged 6 to 14 Years
Slowing Axial Elongation in Pediatric Myopia Using C.A.R.E. Technology
Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population
Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery
Atropine in the Treatment of Myopia Study in Malaysia
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens